Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 8068

Next Previous
Drug Profile

SHR 8068

Alternative Names: SHR-8068

Latest Information Update: 22 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase I/II Urogenital cancer

Most Recent Events

  • 12 Sep 2025 Suzhou Suncadia Biopharmaceuticals plans a phase III trial for Non-small cell lung cancer (Metastatic, Late-stage disease, First line therapy, Combination therapy) in China, in September 2025 (NCT07170995)
  • 07 Aug 2025 Suzhou Suncadia Biopharmaceuticals plans a phase II trial for Gastric cancer (Combination-therapy) in China, in August 2025 (Parenteral, Injection) (NCT07110571)
  • 22 Jul 2025 Phase-II clinical trials in Colorectal cancer (Combination therapy) in China (IV) (NCT07071714)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top